文献速递淋巴瘤

FAB/LMB 96方案治疗期间或治疗后难治或复发成熟B细胞非霍奇金淋巴瘤儿童及青少年的总生存:FAB/LMB 96研究组报告

Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group.
PubMed 文献 · Br J Haematol · 2018-07-09

该研究分析了FAB/LMB 96多药化疗方案注册的1111例新诊断成熟B细胞非霍奇金淋巴瘤患儿中104例(9.4%)在治疗期间或首次完全缓解后出现难治或复发疾病者的生存情况。28例(27%)为难治性疾病,76例(73%)为复发疾病。估计1年和2年总生存率(95%CI)分别为31.5%(23.3-41.0%)和22.3%(15.3-31.4%)。Cox多因素分析显示,乳酸脱氢酶≥2倍正常上限、失败时间>6个月和骨髓失败与总生存独立相关。作者指出需要新的治疗策略来减少新诊断患者的难治和复发,并亟需开发化疗耐药患者的新挽救方案。

要点

  • 1111例注册患者中104例(9.4%)出现难治或复发疾病,其中难治28例(27%),复发76例(73%)。
  • 估计1年总生存率31.5%(95%CI 23.3-41.0%),2年总生存率22.3%(95%CI 15.3-31.4%)。
  • 乳酸脱氢酶≥2倍正常上限(HR=2.86,95%CI 1.57-5.2,P=0.0006)、失败时间>6个月(HR=0.59,95%CI 0.36-0.97,P=0.038)和骨髓失败(HR=2.78,95%CI 1.65-4.68,P=0.0001)与总生存独立相关。

核心结论

  • 新诊断成熟B细胞非霍奇金淋巴瘤患者中难治和复发疾病仍需新的治疗策略,化疗耐药患者亟需新的挽救方案。

研究设计与样本

  • FAB/LMB 96研究组报告,纳入1111例注册的新诊断成熟B细胞非霍奇金淋巴瘤儿童及青少年,接受FAB/LMB 96多药化疗,分析其中104例(9.4%)治疗期间或首次完全缓解后难治或复发患者的生存及预后因素。

主要发现

  • 104例难治或复发患者中,难治性疾病28例(27%),复发疾病76例(73%)。
  • 估计1年总生存率31.5%(95%CI 23.3-41.0%),2年总生存率22.3%(95%CI 15.3-31.4%)。
  • Cox多因素分析显示,乳酸脱氢酶≥2倍正常上限与总生存独立相关(HR=2.86,95%CI 1.57-5.2,P=0.0006)。
  • 失败时间>6个月与总生存独立相关(HR=0.59,95%CI 0.36-0.97,P=0.038)。
  • 骨髓失败与总生存独立相关(HR=2.78,95%CI 1.65-4.68,P=0.0001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We determined the risk factors associated with poor survival in children and adolescents with de novo mature B cell non-Hodgkin lymphoma (B-NHL) who had refractory or relapsed disease during or after the French-American-British mature lymphoma B (FAB/LMB) 96 multi-agent chemotherapy. Among the 1 111 registered on study, 104 patients (9·4%) had refractory disease or disease relapse after first complete remission. Among these 104 patients, 28 (27%) patients had refractory disease and 76 (73%) had relapsed disease. The estimated 1- and 2-year overall survival (OS) (95% confidence interval) was 31·5% (23·3-41·0%) and 22·3% (15·3-31·4%), respectively. Prognostic analysis of OS using a Cox multivariate model showed that factors independently associated with OS included lactate dehydrogenase ≥2 upper normal limit [hazard ratio (HR) = 2·86 (1·57-5·2), P = 0·0006]; time to failure (>6 months) [HR = 0·59 (0·36-0·97), P = 0·038]; and failure in bone marrow [HR = 2·78 (1·65-4·68), P = 0·0001]. New therapeutic strategies are required to significantly reduce refractory disease and disease relapse in patients with newly diagnosed mature B-NHL and, more importantly, there is a critical need to develop novel retrieval approaches in patients with chemotherapy-resistant disease.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Cairo M, Auperin A, Perkins SL, et al. Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group. Br J Haematol. 2018. PMID: 29984828. doi:10.1111/bjh.15491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。